29882-02-8

Upstream product

• 538-75-0 dicyclohexyl-carbodiimide 
• 68897-42-7 N′,N″-diisopropyl-N,N-dimethyl guanidine 
• 69724-53-4 2,3-dicyclohexyl-1,1-diethylguanidine 
• 124-40-3 dimethyl amine 

Downstream Products

• 1370421-42-3 Zr(NMe₂)3(Me₂NC(NCy)2) 
• 4833-42-5 N-phenyl-N',N-dicyclohexylguanidine 
• 124-40-3 dimethyl amine 
• 69724-53-4 2,3-dicyclohexyl-1,1-diethylguanidine 
• 4833-41-4 N,N',N''-tricyclohexylguanidine 
• 1033321-92-4 C₂₁H₃₁N₃ 
• 60006-25-9 N,N'-dicyclohexylpiperidine-1-carboximidamide 
• 60006-28-2 N,N'-dicyclohexylpyrrolidine-1-carboximidamide 

Relevant academic research and scientific papers

Ti-amide catalyzed synthesis of cyclic guanidines from di-/triamines and carbodiimides

A titanacarborane monoamide catalyzed, one-step synthesis of mono/bicyclic guanidines from commercially available di/triamines and carbodiimides is reported. The reaction mechanism is also proposed.

Synthesis of acylguanidine analogues: inhibitors of ADP-induced platelet aggregation

Routine screening of compounds for inhibition of ADP-induced platelet aggregation in vitro revealed that 1'-hexamethylenebis[3-cyclohexyl-3-[(cyclohexylimino)(4-morpholinyl)methyl] urea] was active and represented the first example of a bis(acylguanidine) with possible antithrombotic activity. In order to develop a structure-activity relationship for this class of compounds, we synthesized a number of new bis(acylguanidines). These were tested in vitro, and several analogues were also active. Ex vivo testing revealed that compounds 22, 41, 58, and 70-73 were orally active in rats or guinea pigs.